Overview
ImmuneWatch offers a software platform that annotates the epitope specificity of T-cell receptor sequences, converting TCR repertoires into clinically actionable data. The company provides ImmuneWatch DETECT, which extracts therapy-, vaccine-, or pathogen-specific TCRs from TCR repertoires, available as a machine learning platform for on-premises deployment or through direct collaboration with ImmuneWatch.
Leadership & org chart
In the news
- A few years ago, this question couldn't be answered at all. Eniko Toke, PhD, CSO and co-founder of TREOS THERAPEUTICS, is talking about T cell specificity Knowing not just that T cells showed up in a treated tumour, but exactly what they're reacting to. That's what advanced TCR sequencing and repertoire analysis made possible for TREOS THERAPEUTICS's collaboration with ImmuneWatch, annotating T cells inside patient tumours well enough to tell vaccine-induced responses apart from bystander activity. A capability that didn't exist a
- Can you prove, at the TCR level, that a therapeutic cancer vaccine reaches the tumour it was designed to treat? In a Phase 2 trial with Mayo Clinic, TREOS THERAPEUTICS tested PolyPEPI1018, an off-the-shelf peptide vaccine, combined with the checkpoint inhibitor atezolizumab in metastatic MSS colorectal cancer, a tumour type with very limited response to immunotherapy alone. Eniko Toke, PhD, Chief Scientific Officer and co-founder of TREOS Therapeutics, joins the latest Repertoire Room episode to walk through the translational
- Antibody titres are the standard readout for infectious disease vaccine response, but they only capture half of the immune picture. T-cell immunity is often more durable, and for a number of pathogens it correlates more directly with actual protection than circulating antibody levels do. TCR sequencing combined with epitope-specific annotation makes that T-cell response directly measurable: which antigen-specific clones expanded, when, and to what extent. That level of detail supports comparing vaccine candidates, tracking response
- I recorded a podcast with a cancer vaccine developer on the same day that Moderna/Merck announced their positive melanoma cancer vaccine results. A couple of weeks ago I sat down with Eniko Toke, PhD, CSO and co-founder of TREOS THERAPEUTICS. TREOS designed PolyPEPI1018, an off-the-shelf peptide vaccine, to trigger T cell responses against 7 shared tumour antigens in MSS metastatic colorectal cancer, tumours that are notoriously cold and resistant to checkpoint inhibitors. We chatted about their vaccine design, their Phase 2 trial
- I spent several years in microbiome research before co-founding a company built entirely around T cell receptor sequencing. A recent Cell Reports paper from the University of Antwerp brings both field together. But maybe not with expected results... The team profiled 394 individuals across five data layers, including gut bacteria, blood immune cell composition, whole blood transcriptomics and TCR repertoires. The expectation was that gut microbiome type would shape immune profile. It actually didn't. The two turned out to be
- We teamed up with QIAGEN for a joint grant program on TCR sequencing! Grant winners get free TCR sequencing and in-depth TCR data analysis in service. Check out our website for more information, or register for our webinar with QIAGEN tomorrow to learn more about this opportunity. https://lnkd.in/eNUBxi2x
- Last chance to register for our collaborative webinar with QIAGEN to learn more about our free TCR sequencing grant. https://lnkd.in/eNUBxi2x
- ImmuneWatch is pleased to welcome two new external members to its board: Catherine Sanders and Jurgen Del Favero. Catherine Sanders is an immunopathologist with over 20 years in biotech, including senior commercial roles at Adaptive Biotechnologies. She is Chief Business Officer at iOrganBio. Jurgen Del Favero is a scientific founder and former CTO of Multiplicom, one of Belgium's most successful biotech spin-outs. He now leads genomics strategy at CellCarta. "Adding two board members with proven commercial and R&D track records is
Alumni
Tom BosschaertsDirector of Operations
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.